Your browser doesn't support javascript.
Risk of infections in psoriasis: assessment and challenges in daily management.
De Simone, Clara; Fargnoli, Maria Concetta; Amerio, Paolo; Bianchi, Luca; Esposito, Maria; Pirro, Federico; Potenza, Concetta; Ricceri, Federica; Rongioletti, Franco; Stingeni, Luca; Prignano, Francesca.
  • De Simone C; Institute of Dermatology, Catholic University, Rome, Italy.
  • Fargnoli MC; Dermatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Amerio P; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Bianchi L; Department of Medicine and Aging Science and Dermatologic Clinic, University "G. d'Annunzio", Chieti-Pescara, Italy.
  • Esposito M; Dermatology Unit, Department of Systems Medicine, Tor Vergata University of Rome, Italy.
  • Pirro F; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Potenza C; Institute of Dermatology, Catholic University, Rome, Italy.
  • Ricceri F; Dermatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Rongioletti F; Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy.
  • Stingeni L; Unit of Dermatology, Department of Health Science, University of Florence, Florence, Italy.
  • Prignano F; Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari, via Università 40, 09124 Cagliari, Italy, IRCCS San Raffaele Hospital, Vita Salute University, Milan, Italy.
Expert Rev Clin Immunol ; 17(11): 1211-1220, 2021 11.
Article in English | MEDLINE | ID: covidwho-1483218
ABSTRACT

INTRODUCTION:

In daily practice management of psoriasis, evaluation of risk factors for infections is having a growing influence. Indeed, in psoriatic patients, risk of infections may be due to psoriasis itself, immunomodulatory therapy, and comorbidities that may increase this risk and patient hospitalization. AREAS COVERED Given the greater understanding of psoriasis pathogenesis and the increasing number of treatment options, it is particularly important to customize therapy according to each, single patient; psoriasis features and comorbidities are also essential to tailor treatment goals. EXPERT OPINION In this perspective, the current knowledge on the infectious risk in psoriatic patient, related to comorbidities, such as diabetes mellitus, cardiovascular disease, and chronic obstructive pulmonary, to 'special populations,' to chronic infections, such as latent tuberculosis, chronic hepatitis B and C, and HIV, and to the most recent Covid-19 pandemic scenario, is reviewed and discussed in order to suggest the most appropriate approach and achieve the best available therapeutic option.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Risk Assessment / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Expert Rev Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: 1744666X.2021.1997592

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Risk Assessment / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Expert Rev Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: 1744666X.2021.1997592